MedTrace Logo

Maternal Marijuana Use and Fetal and Infant Outcome

NCT04266314 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2021-02-17

No results posted yet for this study

Summary

Marijuana and cannabis-containing products are growing in popularity and availability in the United States, and use during pregnancy has increased dramatically. The overarching aim of this proposal is to provide pilot data for a submission which will explore the impact of chronic maternal marijuana use (primary or secondary) on fetal functioning, maternal reflective functioning and infant birth and neurodevelopmental outcomes. Chronically marijuana using pregnant women in treatment at the Center for Addiction and Pregnancy will be enrolled and asked to provide information about participants' marijuana and other licit and illicit substance use and feelings about parenting and participants' infant and undergo fetal monitoring at 36 weeks gestation. The neonates will undergo neurobehavioral examination during the first and fourth weeks of life.

Conditions

  • Cannabis Use Disorder
  • Pregnancy Related

Interventions

DEVICE

Maternal-fetal monitoring

Maternal-fetal monitoring evaluates fetal and maternal heart rate, maternal respirations, fetal movement, and maternal skin conductance (a way to monitor emotional response)

OTHER

NICU Network Neurobehavioral Scale

Evaluates neurobehavioral organization, neurological reflexes, motor development, and signs of stress and withdrawal of substance-exposed infants.

Sponsors & Collaborators

Principal Investigators

  • Lauren Jansson, MD · Johns Hopkins University

Eligibility

Min Age
18 Years
Max Age
44 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-10
Primary Completion
2021-02-15
Completion
2021-02-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04266314 on ClinicalTrials.gov